



Celgene Corporation
Investor Relations Department
86 Morris Avenue
Summit, NJ 07901
United States

[Visit IR website](#)
[Sign-up for e-mail alerts](#)

NASDAQ: CELG

Last Trade:	89.61
Trade Time:	4:00 PM ET Mar 16, 2018
Change:	-0.30 (0.334%)
Day Range	89.28 - 91.00
52-Week Range	86.55 - 147.17
Volume	15,039,324

Stock information is provided by eSignal,
stock charts provided by EDGAR Online.
Stock data is delayed approximately 20
minutes.

Company Profile

Celgene Corporation is a global biopharmaceutical company engaged in the discovery, development and commercialization of innovative therapies for the treatment of cancer and immune-inflammatory related diseases. Our portfolio of commercial products include REVLIMID[®], VIDAZA[®], THALOMID[®], POMALYST[®]/IMNOVID[®], ABRAXANE[®], OTEZLA[®], ISTODAX[®] and IDHIFA[®]. The drug candidates in our pipeline are at various stages of preclinical and clinical development. These cand... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- Mar 6, 2018
[Celgene Completes Acquisition of Juno Therapeutics, Inc., Advancing Global Leadership in Cellular Immunotherapy](#)
- Mar 5, 2018
[Celgene Announces Expiration of Cash Tender Offer for Shares of Juno Therapeutics, Inc.](#)
- Feb 27, 2018
[Celgene Provides Regulatory Update on Ozanimod for the Treatment of Relapsing Multiple Sclerosis](#)
- Feb 27, 2018
[Celgene Corporation to Webcast at Upcoming Investor Conferences](#)
- Feb 21, 2018
[Celgene Receives Antitrust Clearance for Juno Acquisition](#)

Financials [\[View all \]](#)

- Feb 7, 2018
[Annual Report \(10-K\)](#)
- Apr 27, 2017
[Proxy Statement \(DEF 14A\)](#)
- Oct 26, 2017
[Quarterly Report \(10-Q\)](#)
- Jul 27, 2017
[Quarterly Report \(10-Q\)](#)
- Apr 27, 2017
[Quarterly Report \(10-Q\)](#)